A phase 1/2a, dose-escalation, safety, and preliminary efficacy study of the RKP00156 vaginal tablet in healthy women and patients with cervical intraepithelial neoplasia 2

CONCLUSION: The safety of RKP00156 was proved with no serious AEs. Although the study did not show any significance in histologic regression and HPV clearance, our findings indicate that RKP00156 may have a possibility of short-term inhibitory effect on HPV replication in patients with higher viral loads.TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT02139267.PMID:38330377 | DOI:10.3802/jgo.2024.35.e52

Source: Journal of Gynecologic Oncology - February 8, 2024 Category: OBGYN Authors: Hyun-Woong Cho Sohyeon Jeong Seung Hun Song Young Tae Kim Jae-Weon Kim Chi-Heum Cho Soo Young Hur Suk-Joon Chang Yong Man Kim Jae Kwan Lee Source Type: research